{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:14:22Z","timestamp":1792134862097,"version":"4.4.0"},"reference-count":21,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T00:00:00Z","timestamp":1317772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>This study assessed <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> mutation prevalence in an unselected cohort of patients with triple\u2010negative breast cancer (BC).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>One hundred ninety\u2010nine patients were enrolled. Triple negativity was defined as &lt;1% estrogen and progesterone staining by immunohistochemistry and HER\u20102\/<jats:italic>neu<\/jats:italic> not overexpressed by fluorescence in situ hybridization. Having given consent, patients had <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> full sequencing and large rearrangement analysis. Mutation prevalence was assessed among the triple\u2010negative BC patients and the subset of patients without a family history of breast\/ovarian cancer. Independent pathological review was completed on 50 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Twenty\u2010one deleterious <jats:italic>BRCA<\/jats:italic> mutations were identified\u201413 in <jats:italic>BRCA1<\/jats:italic> and 8 in <jats:italic>BRCA2<\/jats:italic> (prevalence, 10.6%). In 153 patients (76.9%) without significant family history (first\u2010degree or second\u2010degree relatives with BC aged &lt;50 years or ovarian cancer at any age), 8 (5.2%) mutations were found. By using prior National Comprehensive Cancer Network (NCCN) guidelines recommending testing for triple\u2010negative BC patients aged &lt;45 years, 4 of 21 mutations (19%) would have been missed. Two of 21 mutations (10%) would have been missed using updated NCCN guidelines recommending testing for triple\u2010negative BC patients aged &lt;60 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The observed mutation rate was significantly higher (<jats:italic>P<\/jats:italic> = .0005) than expected based on previously established prevalence tables among patients unselected for pathology. <jats:italic>BRCA1<\/jats:italic> mutation prevalence was lower, and <jats:italic>BRCA2<\/jats:italic> mutation prevalence was higher, than previously described. Additional mutation carriers would have met new NCCN testing guidelines, underscoring the value of the updated criteria. Study data suggest that by increasing the age limit to 65 years, all carriers would have been identified. Cancer 2011;. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26576","type":"journal-article","created":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T14:37:06Z","timestamp":1317825426000},"page":"2787-2795","source":"Crossref","is-referenced-by-count":189,"title":["Prevalence of <i>BRCA<\/i> mutations in an unselected population of triple\u2010negative breast cancer"],"prefix":"10.1002","volume":"118","author":[{"given":"Anne\u2010Renee","family":"Hartman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh R.","family":"Kaldate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Sailer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Grier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbin R.","family":"Endsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Silberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Wenstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Sandbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1109"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg050"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932692100"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.6231"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800456"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.22002","article-title":"Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer","volume":"26","author":"Comen EA","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4725"},{"issue":"15","key":"e_1_2_6_10_2","article-title":"Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA\u2010deficient advanced ovarian cancer","volume":"27","author":"Audeh M","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18","key":"e_1_2_6_11_2","article-title":"Efficacy of BSI\u2010201, a poly (ADP\u2010ribose) polymerase\u20101 (PARP1) inhibitor, in combination with gemcitabine\/carboplatin (G\/C) in patients with metastatic triple\u2010negative breast cancer (TNBC): results of a randomized phase II trial","volume":"27","author":"O'Shaughnessy J","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1237"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0079"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-86"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1480"},{"key":"e_1_2_6_17_2","unstructured":"Myriad Genetic Laboratories I. BRCA1 and BRCA2 Prevalence Tables. Available at:https:\/\/www.myriadpro.com\/bracanalysis\u2010prevalence\u2010tablesAccessed on December 1 2011."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2560"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6529"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0043"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.0719"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31819c1c93"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26576","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:55:13Z","timestamp":1760298913000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,5]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/cncr.26576"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26576","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,5]]}}}